US Edition
Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research - Psychedelic Alpha
Summary by psychedelicalpha.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research - Psychedelic Alpha
FDA Keeps GH Research’s 5-MeO-DMT on Ice as atai and Beckley Surge Ahead • Makary’s Priority Voucher Program Launches, Cites Novel PTSD Treatment as Example • HALT Fentanyl Act Signed by Trump, Could Streamline Schedule I Researcher Registration • Czech President Signs Medical Psilocybin Into Law • Psychedelic Stocks Surge, Compass Recovers from Readout Sell-off • New Zealand’s Regulator Publishes Psychedelics Prescribing Guidance
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
